Perrigo Co. Plc will separate the company’s generics prescription business – which has been a drag on results – to focus on consumer healthcare following a strategic review, sending the drugmaker’s shares down about 8 percent.

Pfizer Inc. reported solid second-quarter 2018 financial results, with total company revenues up two percent operationally.

GlaxoSmithKline aims to turbo-charge the company’s drug discovery engine with a big bet on genetics as its CEO played down the idea of hiving off consumer healthcare.

Pfizer Inc. announced that the company will organize into three businesses: Innovative Medicines, Established Medicines, and Consumer Healthcare.